AUB ScholarWorks

Cervical adenocarcinoma: Moving towards better prevention

Show simple item record Seoud M. Tjalma W.A.A. Ronsse V.
dc.contributor.editor Nov-2011 2017-10-05T15:46:50Z 2017-10-05T15:46:50Z 2011
dc.identifier 10.1016/j.vaccine.2011.09.115
dc.description.abstract Objective: Although cervical screening has led to a significant decline of invasive cervical cancer (ICC) in developed countries, it remains the third leading cause of cancer in women worldwide. While the majority of the decline in ICC can be attributed to a reduction in squamous cell carcinoma (SCC), the incidence of cervical adenocarcinoma (ADC), absolute and relative to SCC, has been rising steadily, especially in younger women. This paper examines oncogenic human papillomavirus (HPV) infections, the risk of developing cervical ADC and its prognosis. It analyzes differences between ADC and SCC and considers current and future methods for prevention. Methods: PubMed, publicly available websites and congress abstracts were searched for data and literature. Results: HPV-16, -18 and -45 account for approximately 90percent of ADC worldwide. Typically, α-7 genotypes, which include HPV-18 and -45, are more commonly associated with ADC than SCC. The difficulty in detecting ADC through screening as well as changing sexual habits and increased HPV transmission may account for its increase; an increase in SCC may not be observed because of improved detection of pre-malignant SCC compared with pre-malignant ADC. HPV testing shows promise for screening women ≥30. years of age, but α-7 genotypes may be underrepresented in precancerous lesions. Clinical trial data indicate that current vaccines have high efficacy against HPV-16-18-related cervical intraepithelial neoplasia. Moreover, these vaccines also demonstrate a different level of protection beyond the HPV vaccine types, therefore increasing the overall vaccine efficacy. Such broad coverage could translate into a considerable reduction in the incidence of ADC. Conclusion: Prophylactic HPV vaccination may have a significant impact on the prevention of ADC and may significantly impact future strategies for primary and secondary prevention of cervical cancer. © 2011 Elsevier Ltd.
dc.format.extent Pages: (9148-9158)
dc.language English
dc.publisher OXFORD
dc.relation.ispartof Publication Name: Vaccine; Publication Year: 2011; Volume: 29; no. 49; Pages: (9148-9158);
dc.source Scopus
dc.title Cervical adenocarcinoma: Moving towards better prevention
dc.type Review
dc.contributor.affiliation Seoud, M., American University of Beirut Medical Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Bliss Street, Box: 113-6044-30C, Beirut, Hamra District, Lebanon
dc.contributor.affiliation Tjalma, W.A.A., Antwerp University Hospital, University of Antwerp, Department of Gynaecological Oncology, Edegem-Antwerpen, Belgium
dc.contributor.affiliation Ronsse, V., GlaxoSmithKline Biologicals, Wavre, Belgium
dc.contributor.authorAddress Seoud, M.; American University of Beirut Medical Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Bliss Street, Box: 113-6044-30C, Beirut, Hamra District, Lebanon; email:
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Obstetrics and Gynecology;
dc.contributor.authorDepartment Obstetrics and Gynecology
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Seoud, M
dc.contributor.authorInitials Tjalma, WAA
dc.contributor.authorInitials Ronsse, V
dc.contributor.authorReprintAddress Seoud, M (reprint author), Amer Univ Beirut, Med Ctr, Dept Obstet and Gynecol, Div Gynecol Oncol, Bliss St,Box 113-6044-30C, Beirut, Lebanon.
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Advisory Committee on Cancer Prevention, 2000, EUR J CANCER, V36, P1473; Altekruse SF, 2003, AM J OBSTET GYNECOL, V188, P657, DOI 10.1067-mob.2003.132; *AM CANC SOC, 2009, WHAT IS CERV CANC; American College of Obstetricians and Gynecologists, 2009, OBSTET GYNECOL, V114, P1409; ANDERSON GH, 1992, OBSTET GYNECOL, V80, P1; [Anonymous], 2002, CERV CANC SCREEN DEV; ANTONCULVER H, 1992, AM J OBSTET GYNECOL, V166, P1507; Anttila A, 2009, EUR J CANCER, V45, P2685, DOI 10.1016-j.ejca.2009.07.017; Anttila A, 2009, EUR J CANCER, V45, P2649, DOI 10.1016-j.ejca.2009.07.020; Anttila A, 2010, BRIT MED J, V340, DOI 10.1136-bmj.c1804; Anttila A, 2004, BRIT J CANCER, V91, P935, DOI 10.1038-sj.bjc.6602069; Arbyn M, 2008, OBSTET GYNECOL, V111, P167, DOI 10.1097-01.AOG.0000296488.85807.b3; Arbyn M, 2008, EUROPEAN GUIDELINES; Arbyn M, 2007, CYTOPATHOLOGY, V18, P133, DOI 10.1111-j.1365-2303.2007.00464.x; Arbyn M, 2010, ANN ONCOL, V21, P448, DOI 10.1093-annonc-mdp471; Arbyn M, 2008, BRIT MED J, V337, DOI 10.1136-bmj.a1284; Ashfaq R, 1999, ACTA CYTOL, V43, P81; Baalbergen A, 2004, GYNECOL ONCOL, V92, P262, DOI 10.1016-j.ygyno.2003.09.001; Badaracco G, 2002, J MED VIROL, V67, P574, DOI 10.1002-jmv.10141; Badaracco G, 2005, INT J ONCOL, V27, P161; Bai HW, 2000, DIAGN CYTOPATHOL, V23, P19, DOI 10.1002-1097-0339(200007)23:119::AID-DC43.0.CO;2-K; BEREK JS, 1985, OBSTET GYNECOL, V65, P46; BERTRAND M, 1987, AM J OBSTET GYNECOL, V157, P21; BOON ME, 1981, CANCER, V48, P768, DOI 10.1002-1097-0142(19810801)48:3768::AID-CNCR28204803183.0.CO;2-L; Bosch FX, 2008, VACCINE, V26, pK1, DOI 10.1016-j.vaccine.2008.05.064; Bosch FX, 2002, J CLIN PATHOL, V55, P244; Brown DR, 2009, J INFECT DIS, V199, P926, DOI 10.1086-597307; Bulk S, 2006, BRIT J CANCER, V94, P171, DOI 10.1038-sj.bjc.6602915; Bulk S, 2007, BRIT J CANCER, V96, P1234, DOI 10.1038-sj.bjc.6603693; Bulk S, 2005, INT J CANCER, V113, P1005, DOI 10.1002-ijc.20678; Burd EM, 2003, CLIN MICROBIOL REV, V16, P1, DOI 10.1128-CMR.16.1.1-17.2003; Burger RA, 1996, J NATL CANCER I, V88, P1361, DOI 10.1093-jnci-88.19.1361; Castellsague X, 2006, J NATL CANCER I, V98, P303, DOI 10.1093-jnci-djj067; Centers for Disease Control and Prevention (CDC), 2010, MMWR-MORBID MORTAL W, V59, P626; Chen RJ, 1999, GYNECOL ONCOL, V73, P184, DOI 10.1006-gyno.1999.5364; Clifford G, 2008, INT J CANCER, V122, P1684, DOI 10.1002-ijc.23282; Cuzick J, 2008, VACCINE, V26, pK29, DOI 10.1016-j.vaccine.2008.06.019; DAVIS JR, 1975, OBSTET GYNECOL, V45, P79; Davy MLJ, 2003, OBSTET GYNECOL, V101, P38, DOI 10.1016-S0029-7844(02)02275-5; Denny L, 2005, JAMA-J AM MED ASSOC, V294, P2173, DOI 10.1001-jama.294.17.2173; de Sanjose S, 2007, LANCET INFECT DIS, V7, P453, DOI 10.1016-S1473-3099(07)70158-5; de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016-S1470-2045(10)70230-8; DEVESA SS, 1984, OBSTET GYNECOL, V63, P605; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016-j.virol.2004.03.033; De Vuyst H, 2008, INT J CANCER, V122, P244, DOI 10.1002-ijc.23045; Dillner J, 2008, BRIT MED J, V337, DOI 10.1136-bmj.a1754; EIFEL PJ, 1995, GYNECOL ONCOL, V59, P38, DOI 10.1006-gyno.1995.1265; EIFEL PJ, 1990, CANCER, V65, P2507, DOI 10.1002-1097-0142(19900601)65:112507::AID-CNCR28206511203.0.CO;2-9; El-Mansi MT, 2006, INT J GYNECOL CANCER, V16, P1025; *EMA, 2010, GARD SUMM PROD CHAR; *EMA, 2011, CERV SUMM PROD CHAR; Ferber MJ, 2003, ONCOGENE, V22, P3813, DOI 10.1038-sj.onc.1206528; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002-ijc.25516; Franco EL, 2008, VACCINE, V26, pA16, DOI 10.1016-j.vaccine.2007.11.069; Gakidou E, 2008, PLOS MED, V5, P863, DOI 10.1371-journal.pmed.0050132; GALLUP DG, 1977, OBSTET GYNECOL, V49, P596; Gien LT, 2010, GYNECOL ONCOL, V116, P140, DOI 10.1016-j.ygyno.2009.09.040; *GLOBOCAN, 2002, GLOBOCAN 2002 CANC I; Goldie SJ, 2007, VACCINE, V25, P6257, DOI 10.1016-j.vaccine.2007.05.058; Gunnell AS, 2007, CANCER EPIDEM BIOMAR, V16, P2641, DOI 10.1158-1055-9965.EPI-07-0278; Han CP, 2009, INT J GYNECOL PATHOL, V28, P489, DOI 10.1097-PGP.0b013e31819e8ab4; Hayes MMM, 1997, CYTOPATHOLOGY, V8, P397, DOI 10.1111-j.1365-2303.1997.tb00570.x; HEPLER TK, 1952, AM J OBSTET GYNECOL, V63, P800; Hildesheim A, 2001, BRIT J CANCER, V84, P1219, DOI 10.1054-bjoc.2001.1779; Hirschowitz L, 2007, DIAGN PATHOL, V2, DOI 10.1186-1746-1596-2-40; HOPKINS MP, 1991, OBSTET GYNECOL, V77, P912; HOROWITZ IR, 1988, GYNECOL ONCOL, V31, P25, DOI 10.1016-0090-8258(88)90265-X; Hudelist G, 2004, GYNECOL ONCOL, V92, P873, DOI 10.1016-j.ygyno.2003.11.035; Insinga RP, 2008, CANCER EPIDEM BIOMAR, V17, P1611, DOI 10.1158-1055-9965.EPI-07-2922; *INT AG RES CANC, 2005, IARC HDB CANC PREV, V10, P201; Irie T, 2000, EUR J SURG ONCOL, V26, P464, DOI 10.1053-ejso.1999.0923; JAWORSKI RC, 1990, SEMIN DIAGN PATHOL, V7, P190; Khan MJ, 2005, J NATL CANCER I, V97, P1072, DOI 10.1093-jnci-dji187; KIM MJ, 2010, IPVC 2010 MONTR CAN; Kitchener HC, 2009, LANCET ONCOL, V10, P672, DOI 10.1016-S1470-2045(09)70156-1; Kitchener HC, 2006, BRIT J CANCER, V95, P56, DOI 10.1038-sj.bjc.6603210; Kjaer SK, 2009, CANCER PREV RES, V2, P868, DOI 10.1158-1940-6207.CAPR-09-0031; KLEINE W, 1989, GYNECOL ONCOL, V35, P145, DOI 10.1016-0090-8258(89)90032-2; Kong CS, 2010, AM J SURG PATHOL, V34, P915, DOI 10.1097-PAS.0b013e3181e3291e; Lacey JV, 2003, CANCER-AM CANCER SOC, V98, P814, DOI 10.1002-cncr.11567; Lacey JV, 2001, CANCER CAUSE CONTROL, V12, P153, DOI 10.1023-A:1008918310055; Lai CH, 2007, INT J CANCER, V120, P1999, DOI 10.1002-ijc.22538; Lee KB, 2006, INT J GYNECOL CANCER, V16, P1569, DOI 10.1111-j.1525-1438.2006.00628.x; Lee KR, 2003, INT J GYNECOL PATHOL, V22, P22, DOI 10.1097-01.PGP.0000040034.16722.5F; Li N, 2011, INT J CANCER, V128, P927, DOI 10.1002-ijc.25396; Liu SL, 2001, CAN MED ASSOC J, V164, P1151; Liu SS, 2008, TUMOR BIOL, V29, P105, DOI 10.1159-000135690; Marchiole P, 2007, GYNECOL ONCOL, V106, P132, DOI 10.1016-j.ygyno.2007.03.009; Mathew A, 2009, ASIAN PAC J CANCER P, V10, P645; Mayor Susan, 2003, BMJ, V327, P948, DOI 10.1136-bmj.327.7421.948-d; Mayrand M, 2007, NEW ENGL J MED, V357, P1579, DOI 10.1056-NEJMoa071430; McCluggage WG, 2002, INT J GYNECOL PATHOL, V21, P11, DOI 10.1097-00004347-200201000-00003; McKeage K, 2011, DRUGS, V71, P465, DOI 10.2165-11206820-000000000-00000; Mesher D, 2010, BRIT J CANCER, V102, P1405, DOI 10.1038-sj.bjc.6605619; MIKUTA JJ, 1969, OBSTET GYNECOL, V33, P753; Munoz N, 2004, INT J CANCER, V111, P278, DOI 10.1002-ijc.20244; Munoz N, 2010, J NATL CANCER I, V102, P325, DOI 10.1093-jnci-djp534; Munoz N, 2002, LANCET, V359, P1093, DOI 10.1016-S0140-6736(02)08151-5; Nakanishi T, 2000, GYNECOL ONCOL, V79, P289, DOI 10.1006-gyno.2000.5935; Noller KL, 2003, OBSTET GYNECOL, V102, P259, DOI 10.1016-S0029-7844(03)00565-9; Ostor A, 1997, OBSTET GYNECOL, V89, P88, DOI 10.1016-S0029-7844(96)00386-9; Paavonen J, 2009, Lancet, V374, P301, DOI 10.1016-S0140-6736(09)61248-4; PAAVONEN J, 2010, IPVC 2010 MONTR CAN; Pak SC, 2007, AUST NZ J OBSTET GYN, V47, P504, DOI 10.1111-j.1479-828X.2007.00788.x; Parkin DM, 2006, VACCINE S3, V24, pS11, DOI 10.1016-j.vaccine.2006.05.111; Peedicayil A, 2006, INT J GYNECOL CANCER, V16, P1591, DOI 10.1111-j.1525-1438.2006.00631.x; Peters WA, 2000, J CLIN ONCOL, V18, P1606; PIMENTA J, 2009, 19 FIGO WORLD C; Pirog EC, 2000, AM J PATHOL, V157, P1055, DOI 10.1016-S0002-9440(10)64619-6; Quinn M, 2006, INT J GYNECOL OBSTET, V95, pS43, DOI 10.1016-S0020-7292(06)60030-1; Richart RM, 1967, CLIN OBSTET GYNECOL, V10, P748, DOI 10.1097-00003081-196712000-00002; ROMANOWSKI B, 2010, IPVC 2010 MONTR CAN; Ronco G, 2010, LANCET ONCOL, V11, P249, DOI 10.1016-S1470-2045(09)70360-2; ROTELIMARTINS CM, 2010, ESPID 2010 NIC FRANC; Sasieni P, 2009, INT J CANCER, V125, P525, DOI 10.1002-ijc.24410; Sasieni P, 2009, BRIT MED J, V339, DOI 10.1136-bmj.b2968; Schiffman M, 2005, VIROLOGY, V337, P76, DOI 10.1016-j.virol.2005.04.002; Schiffman M, 2003, J NATL CANC I MONOGR, V31, P14; SCHIFFMAN M, 2010, IPVC 2010 MONTR CAN; SCHORR M, 2009, LIQUID BASED PAP TES; Schwartz SM, 2001, J CLIN ONCOL, V19, P1906; Shimada M, 2006, GYNECOL ONCOL, V101, P234, DOI 10.1016-j.ygyno.2005.10.004; SHINGLETON HM, 1995, CANCER, V76, P1948, DOI 10.1002-1097-0142(19951115)76:10+1948::AID-CNCR28207613113.0.CO;2-T; Smith HO, 2000, GYNECOL ONCOL, V78, P97, DOI 10.1006-gyno.2000.5826; Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002-ijc.22527; Smith JS, 2003, LANCET, V361, P1159, DOI 10.1016-S0140-6736(03)12949-2; Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001-jama.287.16.2114; STOLER MH, 1991, AM J SURG PATHOL, V15, P28, DOI 10.1097-00000478-199101000-00003; TABATA M, 1987, GYNECOL ONCOL, V28, P255, DOI 10.1016-0090-8258(87)90170-3; TJALMA W, 2010, IPVC 2010 MONTR CAN; TJALMA W, 2010, IGCS 2010 PRAG CZECH; Vinh-Hung V, 2007, BMC CANCER, V7, DOI 10.1186-1471-2407-7-164; Vinokurova S, 2008, CANCER RES, V68, P307, DOI 10.1158-0008-5472.CAN-07-2754; Vizcaino AP, 2000, INT J CANCER, V86, P429, DOI 10.1002-(SICI)1097-0215(20000501)86:3429::AID-IJC203.0.CO;2-D; Vizcaino AP, 1998, INT J CANCER, V75, P536, DOI 10.1002-(SICI)1097-0215(19980209)75:4536::AID-IJC83.0.CO;2-U; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002-(SICI)1096-9896(199909)189:112::AID-PATH4313.0.CO;2-F; Wheeler CM, 2009, J NATL CANCER I, V101, P475, DOI 10.1093-jnci-djn510; *WHO, 2010, WHO ICO INF CTR HUM; Wiley DJ, 2002, CLIN INFECT DIS, V35, pS210, DOI 10.1086-342109; Zaino RJ, 2002, INT J GYNECOL PATHOL, V21, P314, DOI 10.1097-01.PGP.0000035801.90350.90; 1997, CYTOPATHOLOGY, V1997, P8
dc.description.citedCount 18
dc.description.citedTotWOSCount 18
dc.description.citedWOSCount 16
dc.format.extentCount 11
dc.identifier.coden VACCD
dc.identifier.pubmedID 21983356
dc.identifier.scopusID 82555205237
dc.relation.ispartOfISOAbbr Vaccine
dc.relation.ispartOfIssue 49
dc.relation.ispartofPubTitle Vaccine
dc.relation.ispartofPubTitleAbbr Vaccine
dc.relation.ispartOfVolume 29
dc.source.ID WOS:000297525500006
dc.type.publication Journal
dc.subject.otherAuthKeyword Adenocarcinoma
dc.subject.otherAuthKeyword Cross-protection
dc.subject.otherAuthKeyword HPV testing
dc.subject.otherAuthKeyword Human papillomavirus
dc.subject.otherAuthKeyword Prophylactic vaccination
dc.subject.otherAuthKeyword Screening
dc.subject.otherChemCAS Papillomavirus Vaccines
dc.subject.otherIndex Wart virus vaccine
dc.subject.otherIndex cancer classification
dc.subject.otherIndex cancer growth
dc.subject.otherIndex cancer incidence
dc.subject.otherIndex cancer prevention
dc.subject.otherIndex cancer risk
dc.subject.otherIndex cancer screening
dc.subject.otherIndex cancer staging
dc.subject.otherIndex cancer survival
dc.subject.otherIndex cervical adenocarcinoma
dc.subject.otherIndex clinical trial (topic)
dc.subject.otherIndex disease association
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex genotype
dc.subject.otherIndex human
dc.subject.otherIndex Human papillomavirus type 16
dc.subject.otherIndex Human papillomavirus type 18
dc.subject.otherIndex Human papillomavirus type 45
dc.subject.otherIndex infection control
dc.subject.otherIndex lymph node metastasis
dc.subject.otherIndex mass screening
dc.subject.otherIndex multipara
dc.subject.otherIndex obesity
dc.subject.otherIndex oral contraception
dc.subject.otherIndex Papanicolaou test
dc.subject.otherIndex papillomavirus infection
dc.subject.otherIndex practice guideline
dc.subject.otherIndex primary prevention
dc.subject.otherIndex priority journal
dc.subject.otherIndex prognosis
dc.subject.otherIndex review
dc.subject.otherIndex secondary prevention
dc.subject.otherIndex seroprevalence
dc.subject.otherIndex sexual transmission
dc.subject.otherIndex sexuality
dc.subject.otherIndex smoking
dc.subject.otherIndex squamous cell carcinoma
dc.subject.otherIndex trend study
dc.subject.otherIndex tumor recurrence
dc.subject.otherIndex tumor volume
dc.subject.otherIndex uterine cervix carcinoma
dc.subject.otherIndex uterine cervix carcinoma in situ
dc.subject.otherIndex uterine cervix cytology
dc.subject.otherIndex virus detection
dc.subject.otherIndex Adenocarcinoma
dc.subject.otherIndex Carcinoma, Squamous Cell
dc.subject.otherIndex Early Detection of Cancer
dc.subject.otherIndex Female
dc.subject.otherIndex Humans
dc.subject.otherIndex Mass Screening
dc.subject.otherIndex Papillomaviridae
dc.subject.otherIndex Papillomavirus Infections
dc.subject.otherIndex Papillomavirus Vaccines
dc.subject.otherIndex Risk Factors
dc.subject.otherIndex Uterine Cervical Neoplasms
dc.subject.otherKeywordPlus SQUAMOUS-CELL CARCINOMA
dc.subject.otherKeywordPlus HUMAN-PAPILLOMAVIRUS TYPES
dc.subject.otherKeywordPlus UTERINE CERVIX
dc.subject.otherKeywordPlus UNITED-STATES
dc.subject.otherKeywordPlus IN-SITU
dc.subject.otherKeywordPlus INTRAEPITHELIAL NEOPLASIA
dc.subject.otherKeywordPlus ADENOSQUAMOUS CARCINOMA
dc.subject.otherKeywordPlus INVASIVE ADENOCARCINOMA
dc.subject.otherWOS Immunology
dc.subject.otherWOS Medicine, Research and Experimental

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


My Account